Skip to content

Impact of Fish Oil-enriched Lipid Emulsion on Fatty Acid and Inflammatory Response in Infants After Surgery

Impact of Fish Oil-enriched Intravenous Lipid Emulsion in Parenteral Nutrition of Phospholipid Fatty Acid Composition and Inflammatory Response in Infants After Gastrointestinal Surgery.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04511299
Enrollment
12
Registered
2020-08-13
Start date
2020-04-07
Completion date
2020-07-13
Last updated
2020-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Keywords

Parenteral nutrition, Interleukin-1b, Interleukin-8, Lipid emulsion

Brief summary

This study aim to compare the impact of fish oil-enriched intravenous lipid emulsion to standard Intravenous lipid emulsion on fatty acid composition and inflammatory response (IL-1β and IL-8 levels) in infants after gastrointestinal surgery. Our hypothesis is the fish oil-enriched intravenous lipid emulsion can improve the fatty acid composition and lower the inflammatory response.

Detailed description

This study is conducted in infants post gastrointestinal surgery that requires parenteral nutrition for at least 3 days. Subjects are classified into two groups. Group 1 received standard IVFE and group 2 received ω-3-enriched IVFE. The type of intravenous standard and omega-3-enriched fat emulsion used in this study are Lipofundin 20% and SMOFlipid 20%, respectively, both administered for three consecutive days after surgery (72 hours) in 1-4 gram/kilogram/day dosing. The inflammatory response (IL-1β and IL-8 levels) and fatty acid composition are checked from blood plasma. Blood examination is done before the surgery and 3 days after the surgery.

Interventions

Fish oil-enriched intravenous lipid emulsion

OTHERLipofundin 20%

MCT/LCT standard intravenous lipid emulsion

Sponsors

Dr. Soetomo General Hospital
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Hours to 2 Months
Healthy volunteers
No

Inclusion criteria

* willing to participate in this study (through informed consent) * undergo gastrointestinal surgery * get parenteral nutrition for at least 3 days

Exclusion criteria

* chronic diseases * allergic to fish, egg, soy and/or nut proteins

Design outcomes

Primary

MeasureTime frameDescription
Fatty Acids Composition3 days (before surgery and after surgery)The percentage of fatty acid consentration from total fatty acids
Inflammatory response3 days (before surgery and after surgery)Interleukin 1b and Interleukin 8 levels

Secondary

MeasureTime frameDescription
Hemoglobin3 days (before surgery and after surgery)Hemoglobin value in all subjects
Leukocyte3 days (before surgery and after surgery)Leukocyte value in all subjects
C reactive Protein3 days (before surgery and after surgery)C Reactive Protein valuel in all subjects
Albumin3 days (before surgery and after surgery)Albumin value in all subjects

Countries

Indonesia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026